Brachial Plexus Injury Market is Expected to Grow at a CAGR of 12.5% By 2023

Pune, India, September, 2017 /MRFR Press Release/- Market Research Future has a half cooked research report on the global brachial plexus injury market. The global brachial plexus injury market is growing continuously and is expected to grow at a CAGR of 12.5% from 2017 to 2023.

Market Highlights

Increase in the number of major road accidents and availability of drugs for the treatment of accidental injuries drives the Asia Pacific. Presence of prominent market players manufacturing the anti-inflammatory drugs further boost the market growth. The global brachial plexus injury market is expected to grow at a CAGR of 12.5% during the forecast period.

Taste the market data and market information presented through more than 120 market data tables and figures spread over 200 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Brachial plexus injury market research report–Global forecast till 2023.”

Major players in brachial plexus injury market

Some of the key players in the global market are Pfizer (U.S.), Abbvie Inc. (U.S.), Johnson & Johnson (U.S.), GlaxoSmithKline (U.S.), Merck Sharp & Dohme Corp (U.S.), Novartis AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Eli Lily and Company (U.S.), AstraZeneca (U.S.), and Amgen (U.S.).   

Regional Analysis

The global brachial plexus injury market consists of four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa.

The Americas dominate the global brachial plexus injury market. It comprises of two regions namely North America and South America. North America in the largest market owing to increase in the demand of anti-inflammatory drugs and growth of sports medicine in the U.S.

In Europe, rising awareness about types of brachial plexus injury and their treatment as well as precautionary awareness drives this market. Furthermore, increasing prevalence of spinal injuries is found in European nations which further propels the market growth.

Asia Pacific is the fastest growing and potential market for brachial plexus injury, whose growth is attributed to the rising awareness about availability of medications and surgical care.

The Middle East & Africa is expected witness steady growth owing to the rising demand for anti-inflammatory drugs and healthcare resources in this region. 

Segmentation

The brachial plexus injury market is segmented on the basis of types which includes avulsion, rupture, neurapraxia, axonotemesis, neurotemesis and neuroma.

On the basis of drugs, the market is segmented into Nonsteroidal anti-inflammatory drugs, Anticonvulsants, Tricyclic antidepressants and Analgesics.  Nonsteroidal anti-inflammatory drug   is segmented is sub-segmented into celecoxib and naproxen. Anticonvulsants is segmented is sub-segmented into gabapentin. Tricyclic antidepressants is segmented is sub-segmented into nortriptyline and doxepin. Analgesics is segmented is sub-segmented into methadone, oxycodone and others.

On the basis of diagnosis, the market is segmented into clinical examination, electro diagnostic studies and imaging studies. Electro diagnostic studies is segmented is sub-segmented into electromyography, Nerve Conduction Velocity (NCV), SNAP technology, and Somatosensory Evoked Potential (SSEP). Imaging studies is sub-segmented into CT, and MRI.

On the basis of treatment, the market is segmented into therapy and surgery. Therapy is segmented is sub-segmented into physical rehabilitation therapy, aquatic therapy, therapeutic taping, and aquatic therapy. Surgery is sub-segmented into nerve graft, nerve transfer and muscle transfer.

On the basis of indication, the market is segmented into trauma, inflammation, contact sports, tumors, radiation treatment, and others. 

Access Complete Report @ https://www.marketresearchfuture.com/reports/brachial-plexus-injury-market-4369